The Technical Analyst
Check Cap Ltd [CHEK]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Check Cap Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.88% $2.29
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 13.40 mill |
| EPS: | -3.01 |
| P/E: | -0.760 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 5.85 mill |
| Avg Daily Volume: | 0.263 mill |
| RATING 2024-04-23 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.760 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.04x |
| Company: PE -0.760 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.551 (-75.93%) $-1.739 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.03 - 2.55 ( +/- 11.35%) |
| ATR Model: 14 days |
Forecast:
16:00 - $2.29
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.29
Forecast 2: 16:00 - $2.29
Forecast 3: 16:00 - $2.29
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.29 (0.88% ) |
| Volume | 0.0149 mill |
| Avg. Vol. | 0.263 mill |
| % of Avg. Vol | 5.66 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CHEK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CHEK
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.
Last 10 Buy Signals
Latest Press Releases
2024-03-25 19:15:00 - Press Release
Nobul Ai Corp And Check-cap Ltd Enter Into Definitive Business Combination Agreement
Proposed business combination to create a north american technology company with an ai-driven fintech marketplace. combined company to apply for listing on nasdaq and tsx toronto , march 25, 2024 /prnewswire/ -- nobul ai corp. ("nobul") and check-cap ltd.
2023-12-22 10:36:00 - Press Release
Symetryx Comments On Successful Campaign At Check-cap Ltd
Toronto , dec. 22, 2023 /prnewswire/ - symetryx corporation ("symetryx"), a canadian venture company, is pleased to announce that the shareholders of check-cap ltd. (nasdaq: chek) voted overwhelmingly to elect all the director nominees proposed by symetryx at the annual general meeting held on december 18 th 2023.
2023-12-13 12:37:00 - Press Release
Check- Cap Board Member's Statement On The Stand Suggests A Potential Conflict Of Interest With Keystone Dental
Symetryx recommends voting against the keystone dental merger symetryx recommends voting for their qualified independent board nominees time is short - the vote deadline is 11:59 pm est thursday december 14 th 2023 - shareholders may vote or change a previously cast vote until that time toronto , dec. 13, 2023 /prnewswire/ - further to its news release of november 28, 2023, symetryx continues to urge its fellow check-cap ltd. ("check-cap") (nasdaq: chek) shareholders to vote against the keystone dental and for the symetryx slate of highly qualified and independent director nominees.
2023-12-08 11:18:00 - Press Release
Citing The Many Fda Adverse Effects To Keystone Dental - Check-cap Founder Strongly Recommends Voting Against The Keystone Dental Merger Also Recommends Voting For The Symetryx Board Nominees
Toronto , dec. 8, 2023 /prnewswire/ - further to its news release of november 28, 2023, symetryx continues to urge its fellow check-cap ltd. ("check-cap") (nasdaq: chek) shareholders to vote against the keystone dental and for the symetryx slate of highly qualified and independent director nominees.
2023-12-05 15:42:00 - Press Release
Check-cap Founder Strongly Recommends Voting Against The Keystone Dental Merger And For The Symetryx Board Of Directors Nominees
Toronto , dec. 5, 2023 /prnewswire/ - today, symetryx corporation ("symetryx") once again encourages our fellow shareholders of check-cap ltd. ("check-cap") (nasdaq: chek) to review the news release issued by yoav kimchy, phd, the founder and former chief technology officer, and shareholder, of check-cap, who has stated in an open letter to his fellow shareholders that the value of the intellectual property of check-cap was, in essence, disregarded and assigned no monetary value when valuing the keystone dental transaction.
Latest News
2024-03-26 08:35:49 - InvestorPlace
Why Is Check-Cap (CHEK) Stock Up 44% Today?
Check-Cap (NASDAQ: CHEK ) stock is on the rise Tuesday as the clinical stage medical diagnostics company announces a business combination with Nobul AI . This deal will have Check-Cap hand of the reigns of the company to Nobul AI's leadership team and shareholders.
2022-09-08 14:18:18 - Zacks Investment Research
3 Medical Instruments Stocks With Potential to Outperform
Here we discuss ShockWave Medical (SWAV), CheckCap (CHEK) and Biosig Technologies (BSGM) that have the potential to outperform their industry going forward.
2022-02-07 10:19:29 - Benzinga
FDA Gives Green To Check-Cap's Pivotal Study For Capsule-Based Colorectal Cancer Screening Test
The FDA has approved Check-Cap Ltd's (NASDAQ: CHEK) amended Investigational Device Exemption (IDE) application to initiate the U.S. pivotal study of C-Scan. The U.S. pivotal study consists of two parts.
2021-11-02 15:24:03 - PennyStocks
5 Penny Stocks To Buy According To Analysts & Price Targets Up To 175%
Some of the best penny stocks 2021 has offered were some of… The post 5 Penny Stocks To Buy According To Analysts & Price Targets Up To 175% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-10-20 15:58:11 - PennyStocks
Top Penny Stocks To Buy For Under $5 On WeBull
A penny stocks list for the end of October The post Top Penny Stocks To Buy For Under $5 On WeBull appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-07-12 16:58:42 - PennyStocks
Best Biotech Penny Stocks to Buy in July 2021? 6 For Your Watchlist
Biotech penny stocks are in focus; here's 4 to watch right now The post Best Biotech Penny Stocks to Buy in July 2021? 6 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-06-30 14:56:31 - Pulse2
CHEK Stock Price Falls Over 10%: Why It Happened
The stock price of Check Cap Ltd (NASDAQ: CHEK) fell by over 10% during intraday trading. This is why it happened.
2021-06-30 08:12:00 - PRNewsWire
Check-Cap Ltd. Announces $35 Million Registered Direct Offering
ISFIYA, Israel, June 30, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test, to detect polyps before they may transform into colorectal cancer (CRC), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 25,925,926 of the Company's ordinary shares and accompanying short-term warrants to purchase up to an aggregate of 25,925,926 of the Company's ordinary shares in a registered direct offering.
2021-03-30 14:16:00 - InvestorPlace
Mark a Major Medical Milestone with Check-Cap
Why should you check out CHEK stock? An FDA approval, along with an impressive year-end capital position, provide a solid case for Check-Cap.
2021-03-19 07:00:00 - PRNewsWire
Check-Cap Reports Fourth Quarter and Full Year 2020 Financial Results
ISFIYA, Israel, March 19, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free, screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced financial results for the fourth quarter and full year ended December 31, 2020.